Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Inclusion Criteria: Patients must have a histologically confirmed diagnosis of primary breast carcinoma Patient must be naive to chemotherapy at the time of enrollment Patients must have prescribed weekly intravenous adriamycin (doxorubicin) and daily oral cyclophosphamide treatment for early breast cancer The patient must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines Patients must have a Karnofsky index of greater than or equal to 50% Known mild to moderate hepatic, renal or cardiovascular impairment may be enrolled at the discretion of the investigator Exclusion Criteria: Receipt of investigational drug within 30 days before study entry Received any drug with potential anti-emetic effect within 24 hours prior to the start of study-designated chemotherapeutic agent (with the exception of administration of the palonosetron/dexamethasone infusion solution), including the following: 5-HT3 receptor antagonists; dopamine receptor antagonists (metoclopramide); phenothiazine anti-emetics (prochlorperazine, thiethylperazine and perphenazine); diphenhydramine, scopolamine, chlorpheniramine maleate, trimethobenzamide (diphenhydramine will be allowed if given for prophylactic treatment of hypersensitivity reactions associated with the administration of Taxanes); all benzodiazepines; haloperidol, droperidol, tetrahydrocannabinol, or nabilone; any systemic corticosteroid (hydrocortisone, methylprednisolone, prednisone) (topical or inhaled preparations are allowed) Any vomiting, retching or NCI Common Toxicity Criteria version 3.0 grade 2-4 nausea in the 24 hours preceding chemotherapy Ongoing vomiting from any organic etiology Need to receive systemic corticosteroids, except: a) when defined as part of the chemotherapy regimen as a preventative measure for chemotherapy toxicities; b) topical or inhaled preparations; and/or c) when used as rescue medication during the study Known contraindication to 5-HT3 receptor antagonists (including palonosetron) or dexamethasone Need to receive radiotherapy during the study Inability to understand or cooperate with study procedures